-
Understanding The Psilocybin Supply Chain: Every Production Method Explained
Thursday, July 21, 2022 - 4:42pm | 1826Psilocybin is known as the active compound in so-called “magic mushrooms”, yet most psilocybin used in clinical trials today is synthesized in laboratories without the use of biological material. As psychedelics-assisted therapy gains momentum, investors need to understand the...
-
Psyched: CaamTech Raises $22M, Mydecine To Launch Smoking Cessation Trial, Michigan Bill Could Decriminalize Psychedelics
Monday, September 13, 2021 - 1:37pm | 1768Last Week In Psychedelics: CaamTech Raises $22M With A Broad Portfolio Of Novel Psychedelic Drugs Octarine Bio and Clerkenwell Health Partner Up For Clinical Trials Mydecine To Launch Smoking Cessation Clinical Trial With Johns Hopkins University DMT Found To Stimulate Growth Of...
-
CaamTech Raises $22M With A Broad Portfolio Of Novel Psychedelic Drugs
Wednesday, September 8, 2021 - 11:04am | 801CaaMTech, a drug discovery company in the psychedelics space, has closed a $22 million Series A financing round. The company is focused on building a patent library of analytically pure, well-characterized psychedelic drugs for psychiatry and other health purposes. “We have been screening...
-
Psyched: MindMed Enters Psychedelics 2.0, Mind Cure Raises $18M, Mydecine Raises $13M
Wednesday, February 17, 2021 - 12:44pm | 829Mind Cure Closes $18M Raise Mind Cure Health Inc. (CSE:MCUR) recently announced the closing of a CA$23 Million ($18.1 million) offering. The company issued approximately 38 million units, consisting of one share and one half of a share purchase warrant, at CA$0.60 per unit. The proceeds...
-
What Will The Psychedelics Space Look Like In 2021? Experts Weigh In
Monday, January 18, 2021 - 12:43pm | 1182In 2020, psychedelics took the world by storm. Over two dozen companies in the sector became publicly listed. The industry grew closer to federal legalization of the first psychedelic compounds for therapeutic use. With scientific, regulatory and corporate developments becoming...
-
Psyched: Numinus, MAPS To Spearhead MDMA Trials; Vancouver Plans To Decriminalize Drugs
Sunday, December 6, 2020 - 12:52pm | 844Numinus and MAPS Collaborate to Study MDMA in Canada Numinus Wellness (TSXV: NUMI) and the MAPS Public Benefit Corporation have joined forces to bring MDMA-assisted psychotherapy through clinical trials for approval in Canada. The pair will first seek permission to perform a single-arm, open-label...
-
'Psyched': Compass Closes $80M Series B, Danish Scientists Discover Method For Producing Psilocybin From Yeast
Sunday, May 10, 2020 - 4:15pm | 1117Welcome to Psyched, a bi-monthly column covering the most important developments in the industry of medicinal psychedelics. We hope you follow us periodically as we report on the growth of this exciting new industry. CaaMTech Launches Research Collaboration With National Institutes of Health...
-
Former Canopy Growth Exec Jon Cooper Joins CaaMTech Board
Thursday, February 27, 2020 - 5:41pm | 268CaaMTech Inc, a company with expertise in psychedelic chemistry and development of novel psychedelic compounds and formulations, announced Wednesday that former Canopy Growth Corp (NYSE: CGC) executive Jon Cooper has joined the company's board. "Jon brings unique...